# S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML

> **NCT00085709** · PHASE3 · COMPLETED · sponsor: **SWOG Cancer Research Network** · enrollment: 637 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** gemtuzumab ozogamicin
- **OTHER:** observation
- **DRUG:** Cytosine arabinoside
- **DRUG:** Daunomycin

## Key facts

- **NCT ID:** NCT00085709
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2010-03
- **Final completion:** 2014-08
- **Target enrollment:** 637 (ACTUAL)
- **Last updated:** 2015-09-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00085709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00085709, "S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00085709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*